Goldman Sachs analyst David Roman raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $14 and keeps a Neutral rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $18 from $16 at Mizuho
- Tandem Diabetes Care: Strong Buy Rating Backed by Strategic Growth Initiatives and Attractive Valuation
- Tandem Diabetes price target raised to $55 from $51 at Barclays
- Tandem Diabetes price target raised to $18 from $16 at Baird
- Tandem Diabetes Care Reports Record Third-Quarter Sales